Lung medication with different oxygen levels for premature babies
Part of Genetic & congenital, Lungs & breathing clinical trials.
This study tests a lung medication called pulmonary surfactant, given with different oxygen levels, to help very premature babies (born before 32 weeks) who have breathing difficulties. The goal is to see which oxygen level works best with non-invasive breathing support.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is a very premature newborn (born before 32 weeks of pregnancy).
- Your baby has signs of breathing problems and needs breathing help, such as a gentle mask or nasal prongs.
- Your baby does NOT need a breathing tube (mechanical ventilation) right after birth or within the first 2 hours.
- Your baby does NOT have serious health issues like a collapsed lung, complex heart defect, or other major birth problems.
- You have given your permission for your baby to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial gives a medication called surfactant early (when oxygen needs are slightly increased) to very premature babies with breathing trouble. It aims to see if this early treatment helps them breathe better without needing a breathing tube, potentially improving their outcomes.
This trial compares two types of surfactant (Calfactant and Poractant Alfa) given through a less invasive method to very premature babies with breathing problems. It aims to see if one works better at helping them breathe without needing a breathing tube.
This trial tests whether giving surfactant (a substance that helps lungs stay open) to premature babies with Respiratory Distress Syndrome (RDS) through a mask on the throat (supraglottic airway) is safe and effective. It may be an option for babies who need extra oxygen but are not on a breathing tube.
This study tests a new medicine called APC-0101, a type of surfactant, for premature babies with breathing problems (respiratory distress syndrome). It may help their lungs work better and reduce the need for more breathing support.
This trial uses a lung ultrasound score, a type of ultrasound, to decide when to give surfactant (a medicine that helps lungs work) to premature babies born between 27 and 35 weeks of pregnancy. It aims to reduce the need for more breathing support and avoid side effects.
This study tests whether giving a pre-medication before a less invasive lung treatment (surfactant) improves breathing in premature babies. It may help some babies avoid more invasive ventilation while still getting the lung medication they need.
Hear when a new Neonatal Respiratory Distress Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.